Enhanced eIF5A2 has reported to initiate tumor formation, promote tumor cell metastasis and promote drug response, suggesting that targeting eIF5A2 could inhibit tumorigenesis and metastasis as well as enhances the sensitivity of drugs [16,17]. The gene discussed is EIF5A2; the disease is neoplasm.